Literature DB >> 32323449

Urinary exosomes: Potential biomarkers for diabetic nephropathy.

Nisha Sinha1,2, Vivek Kumar2, Veena Puri3, Ritambhra Nada4, Ashu Rastogi5, Vivekanand Jha6, Sanjeev Puri7.   

Abstract

Diabetic nephropathy is the most common diabetic complication culminating often into end-stage renal disease. Classically, it is defined by the presence of albuminuria which has limited ability to be detected at early stages but deterioration in kidney function generally precedes albuminuria. This necessitates the development of newer diagnostic assays for diabetic nephropathy to determine the progression of the disease. Kidney associated diseases with non-albuminuria further complicates a timely diagnosis and thus demands an early biomarker. Urinary exosomes, the nanovesicular entities are released by every epithelial cells of the nephron. Their protein or molecular cargo varies in the diseased state which may provide the pathophysiology of the kidney associated diseases. This drives them to be exploited as non-invasive biomarker. This review thus integrates the recent findings on the significance of the urinary exosomes as diagnostic biomarker in kidney-associated diseases, primarily in diabetic nephropathy.
© 2020 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  biomarker; diabetic nephropathy; exosomes; microRNA

Year:  2020        PMID: 32323449     DOI: 10.1111/nep.13720

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  9 in total

1.  The promising significance of liraglutide combined with dapagliflozin or empagliflozin in the prevention of early diabetic nephropathy.

Authors:  Qin Li; Xing Wang; Aili Guo; Wenxia Zheng; Jin Bi; Yan He; Qiong Luo
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

2.  Intervention Value of Path-Type Health Education on Cognition and Renal Function of Patients with Diabetic Nephropathy.

Authors:  Lianfang Bao
Journal:  Comput Math Methods Med       Date:  2021-12-22       Impact factor: 2.238

3.  FOXA1 Suppresses SATB1 Transcription and Inactivates the Wnt/β-Catenin Pathway to Alleviate Diabetic Nephropathy in a Mouse Model.

Authors:  Hong Zhu; Jiarui Peng; Wei Li
Journal:  Diabetes Metab Syndr Obes       Date:  2021-09-10       Impact factor: 3.168

Review 4.  Colorimetric and Electrochemical Screening for Early Detection of Diabetes Mellitus and Diabetic Retinopathy-Application of Sensor Arrays and Machine Learning.

Authors:  Georgina Faura; Gerard Boix-Lemonche; Anne Kristin Holmeide; Rasa Verkauskiene; Vallo Volke; Jelizaveta Sokolovska; Goran Petrovski
Journal:  Sensors (Basel)       Date:  2022-01-18       Impact factor: 3.576

5.  Fluorescence Imaging Using Enzyme-Activatable Probes for Detecting Diabetic Kidney Disease and Glomerular Diseases.

Authors:  Kentaro Yamada; Tomoaki Takata; Takuji Iyama; Shintaro Hamada; Yukari Mae; Takaaki Sugihara; Hajime Isomoto
Journal:  Int J Mol Sci       Date:  2022-07-24       Impact factor: 6.208

Review 6.  Mass spectrometry-based N-glycosylation analysis in kidney disease.

Authors:  Weifu Ren; Qi Bian; Yan Cai
Journal:  Front Mol Biosci       Date:  2022-08-17

7.  Circular RNAs in Diabetic Nephropathy: Updates and Perspectives.

Authors:  Miao Liu; Junli Zhao
Journal:  Aging Dis       Date:  2022-10-01       Impact factor: 9.968

8.  Exosomal miR-21 from tubular cells contributes to renal fibrosis by activating fibroblasts via targeting PTEN in obstructed kidneys.

Authors:  Sheng Zhao; Wei Li; Weimin Yu; Ting Rao; Haoyong Li; Yuan Ruan; Run Yuan; Chenglong Li; Jinzhuo Ning; Siqi Li; Wu Chen; Fan Cheng; Xiangjun Zhou
Journal:  Theranostics       Date:  2021-08-02       Impact factor: 11.556

9.  Extracellular vesicle-derived AEBP1 mRNA as a novel candidate biomarker for diabetic kidney disease.

Authors:  Yiying Tao; Xing Wei; Yue Yue; Jiaxin Wang; Jianzhong Li; Lei Shen; Guoyuan Lu; Yang He; Shidi Zhao; Fan Zhao; Zhen Weng; Xiahong Shen; Ling Zhou
Journal:  J Transl Med       Date:  2021-07-31       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.